This one-of-a-kind, interactive forum where top diligence experts will discuss best practices and help you develop strategies for preparing for, conducting, and applying the results of the IP due diligence process.

Over the past few years, with many blockbuster drug patents expiring, R&D pipelines drying up, and the evolving challenges for patenting life-sciences inventions, many have coined the current landscape as “anti-patent.” As a result, there has been steady increase in companies looking to collaborate and do deals to protect their assets, maintain market share, and maximize the life of their patent portfolios.

ACI’s 4th Annual Summit on Life Sciences IP Due Diligence is a “think tank” style forum which will help you develop and “perfect” expert strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence.

Interested? Download the 2019 Brochure to Review and You will receive the 2020 brochure when it becomes available
Download 2019 Brochure

Join your colleagues and get the most current, comprehensive information and advice on structuring and managing life sciences IP due diligence, in an environment that will provide incomparable networking opportunities with the players driving the year’s top transactions.


Registration is Now Open. Enjoy Early Bird Rates and Save!

Register Now
THANK YOU TO OUR 2019 CO-CHAIRS
Donna Meuth

Donna Meuth

Associate General Counsel, Intellectual Property
Eisai Inc.

“I’m excited to Co-Chair ACI’s Life Sciences IP Due Diligence conference in Boston this year. The conference offers a great opportunity to gain advice from experts in the field and learn how to avoid issues and mitigate risk in IP due diligences. It’s great to have a conference aimed specifically to the life sciences in view of the many complexities that arise in our transactions.”

Timothy Witkowski

Timothy Witkowski

Global Head, Chemistry Patents
Novartis Institutes for BioMedical Research (NIBR)

“M&A and licensing practice tests the skills of IP attorneys with novel and difficult issues. I am pleased to Co-Chair ACI’s Life Sciences IP Due Diligence conference because it is a great resource for those who practice in this area by focusing on that crucial piece of any life science company’s strategy: how to properly identify, value, and leverage IP through a potential transaction with another party.”

SEE WHO ATTENDED IN THE PAST
  • AMRI
  • Akin Gump Strauss Hauer & Feld LLP
  • Allergan plc
  • Arnold & Porter Kaye Scholer LLP
  • AtriCure Inc
  • Axinn Veltrop & Harkrider LLP
  • BA Ruskin Law LLC
  • BONWRx
  • Beck & Thomas
  • Biogen
  • Blaze Bioscience Inc
  • Boehringer Ingelheim GmbH
  • Boehringer Ingelheim International GmbH
  • Brammer Bio
  • Brinks Gilson & Lione
  • Cantor Colburn LLP
  • Carlson Caspers Vandenburgh Lindquist & Schuman PA
  • Centre for Drug Research and Development
  • Charles River Associates Inc
  • Choate Hall & Stewart LLP
  • Cipla Limited
  • Clark & Elbing LLP
  • Codiak BioSciences
  • DRI Capital Inc
  • Dentsply Sirona Inc
  • Dr. Reddys Laboratories
  • Drinker Biddle & Reath LLP
  • Duane Morris LLP
  • Eisai Inc
  • Evolve BioSystems
  • Finnegan Henderson Farabow Garrett & Dunner
  • Fish & Richardson
  • Fitzpatrick Cella Harper & Scinto
  • Foghorn Therapeutics
  • Forma Therapeutics Inc
  • Futuragene
  • Genentech Inc
  • Gibson Dunn & Crutcher LLP
  • Gilead Sciences
  • Green Griffith & Borg-Breen LLP
  • Heliae
  • Hikma Pharmaceuticals USA Inc
  • Houlihan Lokey
  • Hueschen & Sage PLLC
  • Immunogen Inc
  • Indivior Inc
  • Intellia Therapeutics Inc
  • Ipsen Bioscience Inc
  • Ironwood Pharmaceuticals Inc
  • Jazz Pharmaceuticals
  • Johnson-IP Strategy & Policy Consulting
  • Jounce Therapeutics Inc
  • KSQ Therapeutics Inc
  • King & Spalding LLP
  • Leason Ellis LLP
  • MEDRx
  • Marshall Gerstein & Borun LLP
  • Mayer Brown LLP
  • McDonnell Boehnen Hulbert & Berghoff LLP
  • Merchant & Gould
  • Merck & Co
  • MicroVention Inc.
  • Norris McLaughlin & Marcus P.A.
  • Novartis
  • Novartis Institutes For Biomedical Research
  • Novartis Pharmaceuticals
  • Obalon Therapeutics
  • Ohlandt Greely Ruggiero & Perle LLP
  • Paul Hastings LLP
  • Pearne & Gordon LLP
  • Pepper Hamilton LLP
  • Pieris Pharmaceuticals Inc
  • Porzio Bromberg & Newman P.C.
  • Purdue Pharma LP
  • Purdue Research Foundation
  • Regeneron Pharmaceuticals Inc
  • Roivant Sciences Inc
  • Ropes & Gray LLP
  • Rutgers Law School
  • Sarepta Therapeutics
  • Shire Pharmaceuticals
  • SmartPharm Therapeutics
  • Squire Patton Boggs Us LLP
  • Steptoe & Johnson LLP
  • Sterne Kessler Goldstein & Fox
  • Sun Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Transformative
  • US Court of Appeals for Federal Circuit
  • University of California
  • VBI Vaccines Inc
  • VLP Law Group LLP
  • Wave Life Sciences
  • Wilson Sonsini Goodrich & Rosati PC
Testimonials
Quote Icon

Unique high level sessions, good mix of in-house and outside counsel.

Quote Icon

Hearing from professionals involved in due diligence on a daily basis was very informative.

Quote Icon

Great panels, lots of diversity of practice, and lots of seasoned practitioners.

Quote Icon

The design of the event brought us all together along with room intimacy.

ACI’s Global Series of Life Sciences conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy. Learn More